Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
VERAPAMIL HYDROCHLORIDE
MYLAN PHARMACEUTICALS ULC
C08DA01
VERAPAMIL
120MG
TABLET
VERAPAMIL HYDROCHLORIDE 120MG
ORAL
100/500/1000
Prescription
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Active ingredient group (AIG) number: 0113846001; AHFS:
APPROVED
2009-07-03
PRODUCT MONOGRAPH MYLAN-VERAPAMIL TABLETS (Verapamil Tablets, BP) 80 and 120 mg Antianginal/Antiarrhythmic/Antihypertensive Agent Mylan Pharmaceuticals ULC Date of Preparation: 85 Advance Rd. July 7, 2009 Etobicoke, Ontario M8Z 2S6 Control#: 131047 1 PRODUCT MONOGRAPH MYLAN-VERAPAMIL TABLETS (Verapamil Tablets, BP) 80 and 120 mg THERAPEUTIC CLASSIFICATION Antianginal/Antiarrhythmic/Antihypertensive Agent ACTIONS AND CLINICAL PHARMACOLOGY ANGINA AND ARRHYTHMIA Verapamil hydrochloride is a calcium ion influx inhibitor (calcium entry blocker or calcium ion antagonist). The mechanism of the antianginal and antiarrhythmic effects of verapamil is believed to be related to its specific cellular action of selectively inhibiting transmembrane influx of calcium in cardiac muscle, coronary and systemic arteries and in cells of the intracardiac conduction system. Verapamil blocks the transmembrane influx of calcium through the slow channel (calcium ion antagonism) without affecting, to any significant degree the transmembrane influx of sodium through the fast channel. This results in a reduction of free calcium ions available within cells of the above tissues. Verapamil's antiarrhythmic effects are believed to be brought about largely by its action on the sinoatrial (S-A) and atrioventricular (A-V) nodes. Verapamil depresses A-V nodal conduction and prolongs 2 functional refractory periods. Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization and conduction in depressed atrial fibers. Through this action, it interrupts re-entrant pathways and slows the ventricular rate. Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract. Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory A-V pathway following administration of verapamil (see WARNINGS). Verapamil is a potent smooth muscle relax Izlasiet visu dokumentu